Huadong Medicine Co Ltd
SZSE:000963

Watchlist Manager
Huadong Medicine Co Ltd Logo
Huadong Medicine Co Ltd
SZSE:000963
Watchlist
Price: 32.63 CNY 0.77% Market Closed
Market Cap: 57.2B CNY
Have any thoughts about
Huadong Medicine Co Ltd?
Write Note

Huadong Medicine Co Ltd
Other Long-Term Assets

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Huadong Medicine Co Ltd
Other Long-Term Assets Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Other Long-Term Assets CAGR 3Y CAGR 5Y CAGR 10Y
Huadong Medicine Co Ltd
SZSE:000963
Other Long-Term Assets
ÂĄ1.8B
CAGR 3-Years
31%
CAGR 5-Years
14%
CAGR 10-Years
31%
Sinopharm Group Co Ltd
HKEX:1099
Other Long-Term Assets
ÂĄ5.1B
CAGR 3-Years
1%
CAGR 5-Years
8%
CAGR 10-Years
6%
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
Other Long-Term Assets
ÂĄ2.4B
CAGR 3-Years
1%
CAGR 5-Years
1%
CAGR 10-Years
16%
Jointown Pharmaceutical Group Co Ltd
SSE:600998
Other Long-Term Assets
ÂĄ617.1m
CAGR 3-Years
12%
CAGR 5-Years
15%
CAGR 10-Years
25%
C
China National Medicines Corp Ltd
SSE:600511
Other Long-Term Assets
ÂĄ914.9m
CAGR 3-Years
63%
CAGR 5-Years
33%
CAGR 10-Years
20%
C
China National Accord Medicines Corp Ltd
SZSE:000028
Other Long-Term Assets
ÂĄ1B
CAGR 3-Years
-3%
CAGR 5-Years
16%
CAGR 10-Years
12%
No Stocks Found

Huadong Medicine Co Ltd
Glance View

Market Cap
57.1B CNY
Industry
Health Care

Huadong Medicine Co., Ltd., a key player in China's pharmaceutical landscape, was established with a vision to integrate research, development, manufacturing, and distribution of pharmaceutical products. The company operates a diverse portfolio comprising prescription medicines, over-the-counter products, and active pharmaceutical ingredients. Central to its strategy is a robust focus on innovation and quality, enabling it to effectively cater to various therapeutic areas, including oncology, endocrinology, and nephrology. Huadong Medicine benefits from its substantial investment in research and development, with state-of-the-art facilities that drive advancements and partnerships with global biotech firms, thereby underscoring its commitment to bringing cutting-edge medical solutions to the market. At the heart of Huadong Medicine’s business model is a well-coordinated infrastructure that seamlessly blends manufacturing excellence with a sophisticated distribution network. This dynamic framework ensures the efficient delivery of products across China and into international markets, supporting a significant revenue stream. Additionally, the company's active pharmaceutical ingredients (API) division forms a crucial component of its operations, supplying high-quality raw materials to both domestic and international pharmaceutical companies. By maintaining a strategic balance between product innovation and operational efficiency, Huadong Medicine not only sustains its competitive advantage but also continually scales its presence in the global pharmaceutical industry, carving out a prominent niche in an increasingly competitive arena.

Intrinsic Value
56.24 CNY
Undervaluation 42%
Intrinsic Value
Price

See Also

What is Huadong Medicine Co Ltd's Other Long-Term Assets?
Other Long-Term Assets
1.8B CNY

Based on the financial report for Sep 30, 2024, Huadong Medicine Co Ltd's Other Long-Term Assets amounts to 1.8B CNY.

What is Huadong Medicine Co Ltd's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 10Y
31%

Over the last year, the Other Long-Term Assets growth was 3%. The average annual Other Long-Term Assets growth rates for Huadong Medicine Co Ltd have been 31% over the past three years , 14% over the past five years , and 31% over the past ten years .

Back to Top